Indian healthcare service provider Fortis Healthcare (FHL) has formed a panel to evaluate several competing investment offers, including bids of INR61 billion ($933 million) from TPG Capital-backed Manipal Hospital Enterprises (MHEPL) and INR101 billion...
Qiming Venture Partners has closed two China-focused VC funds – including its sixth US dollar-denominated vehicle and fifth renminbi-denominated vehicle – and a newly-established US healthcare fund, with $1.39 billion in aggregate commitments.
Taimei Medical Technology, a Chinese cloud-based software provider that serves pharmaceutical companies and clinical research organizations (CROs), has raised RMB300 million ($48 million) in Series D funding.
Brandon Capital has committed A$7.7 million ($6 million) to Australian medical technology developer Global Kinetics.
Manipal Hospital Enterprises (MHEPL), an Indian hospital chain backed by TPG Capital, has submitted a revised buyout offer of INR61 billion ($933 million) for the hospital business of domestic rival Fortis Healthcare (FHL).
Biocytogen, a Chinese contract research organization (CRO) that provides genetically engineered mice for drug testing, has raised RMB410 million ($65 million) in a Series C round of funding led by CMB International Capital, an investment arm of China...
Apax Partners has acquired Indian medical devices supplier Healthium Medtech, facilitating exits for TPG Growth and CX Partners.
CICC Capital, the private equity arm of China International Capital Corp, has agreed to invest up to RMB1.8 billion ($286 million) in an onshore subsidiary of Concord Medical, a US-listed healthcare business that abandoned a management-led privatization...
The Riverside Company has sold New Zealand-based animal health devices manufacturer Simcro, along with Work Health Group, an occupational rehabilitation services provider in Australia.
Southern Capital Group is making another attempt to list Qualitas Medical, its Malaysia-based healthcare services provider, on the Singapore Stock Exchange. Partners Group is also an investor in the business.
CD Capital, a Chinese healthcare-focused VC also known as CDBI Partners, has led a $34 million Series B round for CMAB Biopharma, a manufacturing services provider for biologic product developers.
Tencent Holdings has led a RMB500 million ($80 million) Series C round for Miaoshou Doctor, a China-based healthcare services provider.
Chinese VCs Green Pine Capital Partners and Prosperico Ventures have led a $60 million Series A investment in US and China-based cancer diagnosis specialist Singlera Genomics.
Sequoia Capital China has led an oversubscribed $50 million Series C funding round for Chinese biotechnology company Adagene.
Hua Medicine, a Chinese clinical-stage biotechnology company, has closed a combined Series D and Series E funding round at $117.4 million with support from a group of VCs.
IMM Private Equity has fully exited its investments in Korean pharmaceutical developers Handok and Genexine.
The protracted pursuit of Chinese healthcare services provider iKang Healthcare Group appears to have ended, with Yunfeng Capital and Alibaba Group agreeing to buy the business at a valuation of around $1.4 billion.
Beijing Infervision, a Chinese company that develops medical imaging technology empowered by artificial intelligence (AI), has raised RMB300 million ($47 million) in funding from investors including Xianghe Capital.
ChrysCapital has invested $20 million in Indian skin and hair products producer Curatio, providing a partial exit for its private equity backer Fulcrum Ventures.
Cathay Capital Private Equity and OrbiMed have exited Echosens, a France-based medical diagnostic equipment company owned by China’s Inner Mongolia FuRui Medical Science, to European PE firm Astorg.
European asset management firm Tikehau Capital has reached a first close of $50 million on a healthcare-focused early stage investment fund.
Hong Kong is proposing to loosen its listing requirements - with a view to attracting Chinese technology IPOs - in a measured way. However, changes of such significance are rarely implemented smoothly
JW Therapeutics, a China-based clinical stage biopharmaceutical company, has raised $90 million in a Series A round of funding led by Temasek Holdings, Sequoia Capital China, and Yuan Ming Capital.
As the time-honored but largely unprofessional industry of traditional Chinese medicine reinvents itself for the 21st century, private equity could play a role in a massive healthcare overhaul